<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03086785</url>
  </required_header>
  <id_info>
    <org_study_id>HB-B001</org_study_id>
    <nct_id>NCT03086785</nct_id>
  </id_info>
  <brief_title>Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer</brief_title>
  <official_title>Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Medical University Fourth Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of patients who receive
      apatinib single or combined capecitabine for treatment of patients with metastatic her-2
      negative breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 24, 2016</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>evaluated in 24 months since the treatment began</time_frame>
    <description>Baseline to measured date of progression or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>the first day of treatment to death or last survival confirm date,up to 24 months</time_frame>
    <description>Baseline to measured date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>tumor assessment every 6 weeks since the treatment began，up to 24 months</time_frame>
    <description>Baseline to measured progressive disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>tumor assessment every 6 weeks since the treatment began，up to 24 months</time_frame>
    <description>Baseline to measured stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>evaluated in the 24th month since the treatment began according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0</time_frame>
    <description>throughout study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Breast Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>apatinib 500mg qd po or combined Capecitabine 1000mg/m2 bid d1-d14 q3w</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>apatinib 500mg qd po or combined capecitabine 1000mg/m2 bid d1-14 q3w</description>
    <arm_group_label>apatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 70 years old (female)

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          -  Pathologically diagnosed with her-2 negative, ER/PR negative, ER/PR positive after the
             failure of endocrine treatment, and had not more than three chemotherapy regimens
             (must include anthracycline-based and yew class), and the final failure of
             chemotherapy regimens in patients with advanced breast cancer; Note: treatment failure
             include (1) during or after the completion of six months or less disease progress of
             neoadjuvant or adjuvant therapy; (2) rescue treatment in progress within 3 months or
             less

          -  Patients with at least one measurable lesions of the advanced breast cancer，
             measurable lesions has not received radiotherapy or other treatment, unless progress
             after treatment (measuring≥10mm on spiral CT scan, satisfying the criteria in
             RECIST1.1 and WHO);

          -  Major organ function has to meet the following certeria:

               1. For results of blood routine test (without blood transfusion within 14 days)

                    1. HB≥100g/L;

                    2. ANC≥1.5×109/L;

                    3. PLT≥75×109/L;

               2. For results of blood biochemical test：

                    1. TBIL&lt;1.5ULN；

                    2. ALTand AST&lt;2.5ULN, but5&lt;ULN if the transferanse elevation is due to liver
                       metastases；

                    3. Serum creatinine ≤1.25ULN , or calculated creatinine clearance＞45 ml/min(per
                       the Cockcroft-Gault formula); 6.Participants were willing to join in this
                       study, and written informed consent.

        Exclusion Criteria:

          1. The patients with the failure of capecitabine treatment；

          2. The patients with chest wall invasion, or chest wall large canker has a tendency to
             transfer；

          3. Have high blood pressure and antihypertensive drug treatment can not control (systolic
             blood pressure &gt; 140 mmHg, diastolic blood pressure &gt; 90 mmHg), with classⅡand above
             coronary heart disease, unable to control arrhythmia (including QTc lengthened women &gt;
             470 ms) and classⅢ-Ⅳcardiac insufficiency; or Left ventricular ejection fraction
             (LVEF) &lt; 50%；

          4. A variety of factors influencing oral drugs (such as unable to swallow, after
             resection of the gastrointestinal, chronic diarrhea and intestinal obstruction, etc.)；

          5. Has a history of bleeding, the clinical significance of bleeding symptoms, patients
             with definite bleeding tendency, such as gastrointestinal bleeding, bleeding ulcers,
             baseline period （+ +）and above of defecate occult blood, vasculitis, etc；

          6. Received a major surgery within 4 weeks or severe traumatic injury, fractures, or has
             a poor healing wound；

          7. Allergic to apatinib and supplementary material；

          8. Patients with active brain metastases;

          9. Patients with pregnant or planning a pregnancy;

         10. The researchers think inappropriate.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>cuizhi Geng, archiat</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebei Medical University Fourth Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>zefei Jiang, archiat</last_name>
    <role>Principal Investigator</role>
    <affiliation>The 307th Hospital of Chinese Peoples' Liberation Army</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>cuizhi Geng, archiat</last_name>
    <phone>0311-66696310</phone>
    <email>gengcuizhi@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>ShiJiazhuang</city>
        <state>Hebei</state>
        <zip>050019</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cuizhi Geng, archiater</last_name>
      <phone>0311-66696310</phone>
      <email>gengcuizhi@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2017</study_first_posted>
  <last_update_submitted>January 14, 2018</last_update_submitted>
  <last_update_submitted_qc>January 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

